Philadelphia, July 29, 2021 / PRNewswire /- FinPay LLCAnnounced an agreement to be recognized as a leader in pre-care payments and patient engagement Spark Biomedical, Inc. , TexasThe sparrow therapy system, a base medical device company, is the developer of the first FDA-approved, drug-free, personalized wearable neurostimulation solution for opioid withdrawal. Through this agreement, the two companies will address the opioid crisis by combining their core expertise to provide both technological therapeutic innovation and enhanced pre-care financial experience in the behavioral health care market.
FinPay, LLC and Spark Biomedical, Inc.Is partnering to combat opioid addiction in the behavioral health market
The opioid epidemic United States of America And it became an accelerator for the opioid crisis. In fact, the highest number of drug overdose deaths in the United States in 12 months was in 2020, reaching just over 93,000.1 — Opioid use disorder is an important part of this number. The recent 29% increase in deaths from overdose, especially the opioid crisis, is expected to increase as the COVID-19 pandemic prolongs.
Those seeking help in overcoming opioid use disorder (OUD) face some difficult barriers, the fear of painful withdrawal, and the overall cost of treatment. The FinPay-Spark Biomedical partnership is designed to smooth the path to treatment and empower behavioral healthcare facilities with better tools and resources through opioid withdrawal. Only then will patients receive the deeper behavioral care needed to address the underlying cause of OUD.
“We are excited to partner with FinPay to increase patient access to the Sparrow Therapy System through an innovative payment system,” he said. Daniel Powell, CEO of Spark Biomedical. “Together, we want to make it easier for patients with opioid use disorders to get the help they need to overcome painful withdrawal symptoms without having to worry about initial cost barriers. . “
“Spark Biomedical has a proven track record of dealing with opioid withdrawal and is FDA approved. January 5, 2021, “Said Tim Kowalski, CEO of FinPay. “We are excited to offer payment programs to ease the burden on patients who need opioid withdrawal programs. These programs are over 11.5 million Americans suffering from opioid addiction or addiction. May help people. “
FinPay is a fully managed technology solution for patient financial management that enhances patient financial experience through pre-care engagement, enhances healthcare financial literacy, advocates cost transparency and offers affordable payment options. By doing so, we are working to resolve the affordable medical crisis. While regaining consumer confidence in the American healthcare system.
Spark Biomedical, Inc.teeth TexasThe developer of a personalized, wearable neurostimulation solution that does not use the first drug to alleviate opioid withdrawal, backed by evidence from a double-blind, randomized controlled trial in patients with opioid use disorders. A medical device company.
The spider therapy system uses percutaneous auricular nerve stimulation (tAN) to treat withdrawal symptoms by stimulating the nerves around the ear. Wearable Louisa Pieces are designed to be worn up to 24 hours a day during opioid reduction or as prescribed to help reduce withdrawal symptoms.
The company’s vision of igniting a bright future for people suffering from opioid use disorders and addictions is underpinned by a unique blend of scientific expertise, innovation and deep experience in the medical device industry.
Spark Biomedical Media Contact
Senior Vice President of Marketing & Communications
Spark Biomedical, Inc.And FinPay, LLC Partners to Fight Opioid Addiction | State
Source link Spark Biomedical, Inc.And FinPay, LLC Partners to Fight Opioid Addiction | State